BioPharm International
July 01, 2010
Issue PDF
23
7
Robust Strategies to Optimize Processes
July 01, 2010
Features
23
7
Apply risk management principles to monitor outsourced activities.
July 01, 2010
Burrill on Biotech
23
7
After a bright start to the year, some of biotech's blue chip companies have seen their early gains turn into losses.
July 01, 2010
Perspectives on Outsourcing
23
7
How much to spend on early development, whether to use your CMO's proprietary cell line, and other outsourcing advice.
July 01, 2010
Features
23
7
Identify the best experimentation methods for the data you need.
July 01, 2010
Compliance Notes
23
7
By identifying and eliminating non-value-added activities, drug manufacturers can avoid falling into the same cost-traps in the future.
July 01, 2010
From the Editor
23
7
A single standard should apply to all comparability exercises for biologics, be they for biosimilars or manufacturing changes.
July 01, 2010
Final Word
23
7
USP is advancing efforts to develop a guidance for evaluating bioassays.
July 01, 2010
Features
23
7
The HMS174 strain, in the absence or presence of excess phosphate, can metabolize acetate efficiently.
July 01, 2010
Features
23
7
Twelve lessons of what to do and what not to do to avoid quality problems.
July 01, 2010
Regulatory Beat
23
7
More information may be available on drug approvals, prices, and research to expand public understanding of regulatory policies.